HXP089 / Fujian Haixi New Pharmaceutical - LARVOL DELTA

Haixi Pharma Wins NMPA Clearance for New Glioblastoma Drug HXP089 (TipRanks) - "The compound, developed via the firm’s MultiSel-Opt platform, is designed as a selective multi-target small-molecule with strong blood-brain barrier penetration to address the limitations of current single-target glioblastoma treatments."

New trial • Glioblastoma

Fujian Haixi Pharmaceuticals…is pleased to announce that the Investigational New Drug (IND) application for HXP089…for the treatment of glioblastoma (GBM), has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), permitting the conduct of relevant clinical studies (HKEXnews) - "HXP089 is a next-generation selective multi-target small-molecule drug candidate developed by Haixi Pharmaceuticals based on its proprietary small-molecule drug discovery platform - the MultiSel-Opt platform....This approval will support the conduct of relevant clinical studies to evaluate the safety, tolerability and preliminary efficacy profile of HXP089 in the target patients."

New trial • Glioblastoma